Botulinum toxin should be first-line treatment for poststroke spasticity.
Sheean
Geoffrey
G
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D003000:Clonidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D020521:Stroke / Q000150:complications*; D017741:Survivors; D034941:Upper Extremity / Q000503:physiopathology
D018726:Anti-Dyskinesia Agents; D009125:Muscle Relaxants, Central; C023754:tizanidine; D001905:Botulinum Toxins; D003000:Clonidine